Immune dysfunction and micrometastases in women with breast cancer

Cytokines produced by T lymphocytes are critical to the efficacy of a given immune response and dysregulation of immune responses may play a role in cancer progression. We assessed the intracellular cytokine profiles of T cells in the peripheral blood of women with breast cancer and explored the relationship of these responses with the presence of cancer in lymph nodes and bone marrow. Peripheral blood lymphocytes from 84 patients and 26 healthy volunteers were analyzed by 4-color flow cytometry for surface markers and for intracellular cytokines. Bone marrow samples from some of these patients were also collected and analyzed for the presence of epithelial cells (micrometastases) by flow cytometry. The percentages of both CD4+ and CD8+ cells producing type1 (IL-2, IFN-γ or TNF-α) and type 2 (IL-4) were significantly lower in patients with breast cancer compared to healthy controls. These results indicate a general immune dysfunction in these patients as opposed to a shift in the balance of type1 and type2 cells. These dysregulated T cell responses did not correlate with age, stage of disease, or nodal status. However, we did observe a correlation between number of micrometastases in the bone marrow and T cell responsiveness.

[1]  H. Maecker,et al.  Cytokine flow cytometry: multiparametric approach to immune function analysis. , 2003, Cytotherapy.

[2]  W. Eiermann,et al.  Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. , 1994, British Journal of Cancer.

[3]  S. Braun,et al.  Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.

[4]  M. Tan,et al.  Assessment of host immune response in breast cancer patients. , 1986, Cancer detection and prevention.

[5]  Imagawa,et al.  An assessment of the immunological environment based on intratumoral cytokine production in renal cell carcinoma , 1999, BJU international.

[6]  J. Punnonen,et al.  Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors , 1998, Cancer.

[7]  V. Maino,et al.  Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression. , 1998, Cytometry.

[8]  W. Garner,et al.  Human breast cancer and impaired NK cell function , 1983, Journal of surgical oncology.

[9]  E. Maraskovsky,et al.  IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. , 1989, Journal of immunology.

[10]  C. Heusser,et al.  Detection of intracellular cytokines by flow cytometry. , 1993, Journal of immunological methods.

[11]  J. Kovarik,et al.  Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. , 2002, Neoplasma.

[12]  P. Ferrari,et al.  Long-term monitoring of cell-mediated immunity in disease-free breast cancer patients: a preliminary retrospective study. , 2002, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[13]  J Lee,et al.  Perceived social support and tumor estrogen/progesterone receptor status as predictors of natural killer cell activity in breast cancer patients. , 1990, Psychosomatic medicine.

[14]  G. Trinchieri,et al.  Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells , 1993, The Journal of experimental medicine.

[15]  S. Romagnani.  Human TH1 and TH2 subsets: doubt no more. , 1991, Immunology today.

[16]  R. Elliott,et al.  Comparison of estrogen and progesterone receptor status to lymphocyte immunity against tumor antigens in breast cancer patients , 2004, Breast Cancer Research and Treatment.

[17]  T. Dimpfl,et al.  Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.

[18]  V. Maino,et al.  Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. , 1998, Journal of immunological methods.

[19]  J. Chipeta,et al.  Intracellular cytokine profile of T cells from children with acute lymphoblastic leukemia , 2000, Cancer Immunology, Immunotherapy.

[20]  M. de Carli,et al.  An update on human Th1 and Th2 cells. , 1997, International archives of allergy and immunology.

[21]  G. Gyte,et al.  Phytohaemagglutinin responsiveness of peripheral lymphocytes and survival in patients with primary breast cancer , 1989, Breast Cancer Research and Treatment.

[22]  S. Romagnani,et al.  The Th1/Th2 paradigm. , 1997, Immunology today.

[23]  S. Takeuchi,et al.  Impaired production of Th1 cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients. , 1998, Anticancer research.

[24]  P. Ferrari,et al.  Cell-mediated immunity in breast cancer patients. , 1996, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[25]  J. Petros,et al.  Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status , 2000, Breast Cancer Research and Treatment.

[26]  C. Hsieh,et al.  Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. , 1993, Science.

[27]  E. Angevin,et al.  Analysis of T‐cell immune response in renal cell carcinoma: Polarization to type 1‐like differentiation pattern, clonal T‐cell expansion and tumor‐specific cytotoxicity , 1997, International journal of cancer.

[28]  S. Takeuchi,et al.  Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients , 1999, Cancer Immunology, Immunotherapy.

[29]  M L Lesser,et al.  Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[31]  R. Elliott,et al.  Evaluation of lymphocyte immunity in breast cancer patients , 2004, Breast Cancer Research and Treatment.

[32]  R. Coffman,et al.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. , 1989, Annual review of immunology.

[33]  C. Casciani,et al.  Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression , 1996, Cancer Immunology, Immunotherapy.

[34]  V. Maino,et al.  Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. , 1995, Blood.

[35]  D. Easton,et al.  Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. , 1991, European journal of cancer.

[36]  R. Holle,et al.  Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.

[37]  M. Steurer,et al.  Increase of regulatory T cells in the peripheral blood of cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  M. Clerici,et al.  Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases , 1996, Clinical microbiology reviews.

[39]  R. Zeillinger,et al.  Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal study. , 1995, British Journal of Cancer.

[40]  V. Maino,et al.  Immunofluorescence Analysis of T-Cell Responses in Health and Disease , 2000, Journal of Clinical Immunology.

[41]  J. Kirkwood,et al.  Estrogen receptor concentration and social factors as predictors of natural killer cell activity in early-stage breast cancer patients. Confirmation of a model. , 1990, Natural immunity and cell growth regulation.